A guide for the generation of repositories of clinical samples for research on Chagas disease.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
Aug 2024
Historique:
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 15 8 2024
Statut: epublish

Résumé

Chagas disease, caused by the parasite Trypanosoma cruzi, affects over 6 million people, mainly in Latin America. Two different clinical phases, acute and chronic, are recognised. Currently, 2 anti-parasitic drugs are available to treat the disease (nifurtimox and benznidazole), but diagnostic methods require of a relatively complex infrastructure and trained personnel, limiting its widespread use in endemic areas, and the access of patients to treatment. New diagnostic methods, such as rapid tests (RDTs) to diagnose chronic Chagas disease, or loop-mediated isothermal amplification (LAMP), to detect acute infections, represent valuable alternatives, but the parasite's remarkable genetic diversity might make its implementation difficult. Furthermore, determining the efficacy of Chagas disease treatment is complicated, given the slow reversion of serological anti-T. cruzi antibody reactivity, which may even take decades to occur. New biomarkers to evaluate early therapeutic efficacy, as well as diagnostic tests able to detect the wide variety of circulating genotypes, are therefore, urgently required. To carry out studies that address these needs, high-quality and traceable samples from T. cruzi-infected individuals with different geographical backgrounds, along with associated clinical and epidemiological data, are necessary. This work describes the framework for the creation of such repositories, following standardised and uniform protocols, and considering the ethical, technical, and logistic aspects of the process. The manual can be adapted according to the resources of each laboratory, to guarantee that samples are obtained in a reproducible way, favouring the exchange of data among different work groups, and their generalizable evaluation and analysis. The main objective of this is to accelerate the development of new diagnostic methods and the identification of biomarkers for Chagas disease.

Identifiants

pubmed: 39146233
doi: 10.1371/journal.pntd.0012166
pii: PNTD-D-23-01635
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0012166

Informations de copyright

Copyright: © 2024 Martínez-Peinado et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Nieves Martínez-Peinado (N)

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, Barcelona, Spain.
Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.

Juan Carlos Gabaldón-Figueira (JC)

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, Barcelona, Spain.

Roberto Rodrigues Ferreira (R)

Laboratory of Innovations in Therapies, Education and Bioproducts, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (LITEB-IOC/Fiocruz), Rio de Janeiro, Brazil.
Laboratory of Applied Genomics and Bioinnovations, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, (LAGABI-IOC/Fiocruz), Rio de Janeiro, Brazil.

María Carmen Thomas (M)

Instituto de Parasitología y Biomedicina López Neyra, Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), PTS-Granada, Granada, Spain.

Manuel Carlos López (MC)

Instituto de Parasitología y Biomedicina López Neyra, Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), PTS-Granada, Granada, Spain.

Tania Cremonini Araújo-Jorge (T)

Laboratory of Innovations in Therapies, Education and Bioproducts, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (LITEB-IOC/Fiocruz), Rio de Janeiro, Brazil.

Belkisyolé Alarcón de Noya (B)

Instituto de Medicina Tropical, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela.

Soledad Berón (S)

Fundación Mundo Sano, Buenos Aires, Argentina.

Janine Ramsey (J)

Centro Regional de Investigación en Salud Pública (CRISP), Instituto Nacional de Salud Pública (INSP), Tapachula, Chiapas, México.

Irene Losada Galván (I)

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, Barcelona, Spain.
Hospital Universitario 12 de Octubre, Madrid, Spain.

Alejandro Gabriel Schijman (AG)

Laboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres" - INGEBI-CONICET, Buenos Aires, Argentina.

Adriana González Martínez (A)

Departamento de Investigación, Salvando Latidos A.C., Guadalajara, Mexico.
Departamento de Investigación, Instituto Cardiovascular de Mínima Invasión (ICMI), Guadalajara, Mexico.

Andrés Mariano Ruiz (A)

Instituto Nacional de Parasitología "Dr Mario Fatala Chaben" ANLIS MALBRÁN, Ministerio de Salud, Buenos Aires, Argentina.
CONICET, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.

Gimena Rojas (G)

Universidad Mayor de San Simón and Fundación CEADES, Cochabamba, Bolivia.

Roberto Magalhães Saraiva (R)

Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brasil.

Oscar Noya-González (O)

Instituto de Medicina Tropical, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela.
Cátedra de Parasitología, Escuela ¨Luís Razetti" Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela.
Centro para Estudios Sobre Malaria, Instituto de Altos Estudios "Dr. Arnoldo Gabaldón", Ministerio del Poder Popular para la Salud (MPPS), Caracas, Venezuela.

Andrea Gómez (A)

Fundación Mundo Sano, Buenos Aires, Argentina.

Rosa A Maldonado (RA)

Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas, United States of America.

Jimmy Pinto (J)

Universidad Mayor de San Simón and Fundación CEADES, Cochabamba, Bolivia.

Faustino Torrico (F)

Universidad Mayor de San Simón and Fundación CEADES, Cochabamba, Bolivia.

Ivan Scandale (I)

Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.

Fernán Agüero (F)

Instituto de Investigaciones Biotecnológicas (IIB)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín, Buenos Aires, Argentina.
Escuela de Bio y Nanotecnologías (EByN), Universidad de San Martín (UNSAM), San Martín, Buenos Aires, Argentina.

María-Jesús Pinazo (MJ)

Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.
CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (CIBERINFEC, ISCIII), Madrid, Spain.

Joaquim Gascón (J)

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, Barcelona, Spain.
CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (CIBERINFEC, ISCIII), Madrid, Spain.

Alejandro Marcel Hasslocher-Moreno (AM)

Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brasil.

Julio Alonso-Padilla (J)

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, Barcelona, Spain.
CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (CIBERINFEC, ISCIII), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH